Patricia Bradford
@im-a-nobody.bsky.social
Crowdsourcing some information: For the IMARI meeting we are doing a retrospective on projects highlighted in the New Agents sessions at ICCAC/Microbe in the past and are missing info for yrs 2015 and beyond. Did you or a colleague speak in one of those sessions? Please reply in the comments
#IDSky
#IDSky
July 31, 2025 at 2:30 PM
Crowdsourcing some information: For the IMARI meeting we are doing a retrospective on projects highlighted in the New Agents sessions at ICCAC/Microbe in the past and are missing info for yrs 2015 and beyond. Did you or a colleague speak in one of those sessions? Please reply in the comments
#IDSky
#IDSky
So excited for this meeting- a long overdue follow on to ICAAC. Submit your abstracts and hope to see you there. #IDSky
imari.org
imari.org
IMARI 2026
Visit the post for more.
imari.org
July 24, 2025 at 2:19 PM
Check out this new scheme for class D b-lactamases. SAND: a comprehensive annotation of class D β-lactamases using structural alignment-based numbering | Antimicrobial Agents and Chemotherapy journals.asm.org/doi/10.1128/...
SAND: a comprehensive annotation of class D β-lactamases using structural alignment-based numbering | Antimicrobial Agents and Chemotherapy
Class D β-lactamases (DBLs) form a large family with nearly 1,300 identified members in the β-Lactamase Database (Fig. S1, www.bldb.euhttp://www.bldb.eu/) (1). They are produced mainly by Gram-negative bacteria, with some by Gram-positive bacteria (2). DBLs are an important mechanism of resistance to β-lactam antibiotics, including carbapenems, one of last resort treatments to infections in hospitalized patients (3). The production of class D β-lactamases is a major public health concern, as they can often transfer between different bacterial species, allowing resistance to spread quickly and widely. Some members were found to be membrane-bound and are secreted via outer membrane vesicles (OMVs) to contribute further in antimicrobial resistance dissemination (4). Their mechanism of action involves a catalytic serine, as in classes A and C β-lactamases, since all share the conserved SXXK tetrad and KXG triad (3).
journals.asm.org
June 3, 2025 at 3:19 PM
Check out this new scheme for class D b-lactamases. SAND: a comprehensive annotation of class D β-lactamases using structural alignment-based numbering | Antimicrobial Agents and Chemotherapy journals.asm.org/doi/10.1128/...
Such a good book
⭐️SALE⭐️
Read abt the Black Angels who risked their lives caring for TB patients during a dreadful time in history: the pre-antibiotic age of the Great Depression in country entrenched in the horror of Jim Crow
And helped cure TB
And were forgotten
@nadinesmith.bsky.social
@madhupai.bsky.social
Read abt the Black Angels who risked their lives caring for TB patients during a dreadful time in history: the pre-antibiotic age of the Great Depression in country entrenched in the horror of Jim Crow
And helped cure TB
And were forgotten
@nadinesmith.bsky.social
@madhupai.bsky.social
May 25, 2025 at 1:31 PM
Such a good book
The 2025 Vivli AMR Surveillance Data Challenge, funded by Johnson & Johnson, Paratek, Pfizer, and an NIH award* is now OPEN. Head to lnkd.in/djaXB-PX to read about the challenge and how to enter. Expressions of interest must be received by 26-May-2025. #AMR
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
May 2, 2025 at 11:16 AM
The 2025 Vivli AMR Surveillance Data Challenge, funded by Johnson & Johnson, Paratek, Pfizer, and an NIH award* is now OPEN. Head to lnkd.in/djaXB-PX to read about the challenge and how to enter. Expressions of interest must be received by 26-May-2025. #AMR
Reposted by Patricia Bradford
Please join Vivli at NIH’s Data Sharing and Reuse Seminar Series: The Vivli AMR Data Challenge as a Use Case | Friday, March 14 at 12:00 pm ET | Register at scgcorp.zoom.us/webinar/regi...
March 5, 2025 at 8:59 PM
Please join Vivli at NIH’s Data Sharing and Reuse Seminar Series: The Vivli AMR Data Challenge as a Use Case | Friday, March 14 at 12:00 pm ET | Register at scgcorp.zoom.us/webinar/regi...
Reposted by Patricia Bradford
Science: sometimes it just takes a little protocol tweak
Petri (1887) Centralblatt fur Bacteriologie und Parasitenkunde
“A minor modification of the plating technique of Koch...under these conditions, contamination from airborne germs rarely occurs”
His modification?
A͓̽ ͓̽L͓̽I͓̽D͓̽ ͓̽F͓̽O͓̽R͓̽ ͓̽T͓̽H͓̽E͓̽ ͓̽A͓̽G͓̽A͓̽R͓̽ ͓̽D͓̽I͓̽S͓̽H͓̽
Petri (1887) Centralblatt fur Bacteriologie und Parasitenkunde
“A minor modification of the plating technique of Koch...under these conditions, contamination from airborne germs rarely occurs”
His modification?
A͓̽ ͓̽L͓̽I͓̽D͓̽ ͓̽F͓̽O͓̽R͓̽ ͓̽T͓̽H͓̽E͓̽ ͓̽A͓̽G͓̽A͓̽R͓̽ ͓̽D͓̽I͓̽S͓̽H͓̽
January 28, 2025 at 4:23 AM
Science: sometimes it just takes a little protocol tweak
Petri (1887) Centralblatt fur Bacteriologie und Parasitenkunde
“A minor modification of the plating technique of Koch...under these conditions, contamination from airborne germs rarely occurs”
His modification?
A͓̽ ͓̽L͓̽I͓̽D͓̽ ͓̽F͓̽O͓̽R͓̽ ͓̽T͓̽H͓̽E͓̽ ͓̽A͓̽G͓̽A͓̽R͓̽ ͓̽D͓̽I͓̽S͓̽H͓̽
Petri (1887) Centralblatt fur Bacteriologie und Parasitenkunde
“A minor modification of the plating technique of Koch...under these conditions, contamination from airborne germs rarely occurs”
His modification?
A͓̽ ͓̽L͓̽I͓̽D͓̽ ͓̽F͓̽O͓̽R͓̽ ͓̽T͓̽H͓̽E͓̽ ͓̽A͓̽G͓̽A͓̽R͓̽ ͓̽D͓̽I͓̽S͓̽H͓̽
This conference is long awaited and much needed following the demise of ICAAC. I can’t wait to see how this develops @asm.org
asm.org/Press-Releas...
asm.org/Press-Releas...
ASM and IDSA to Launch New Conference on AMR
ASM and IDSA partner to create an annual AMR conference to explore the latest advances in antimicrobial drug discovery and development, mechanisms of resistance, pharmacological aspects and more.
asm.org
December 14, 2024 at 12:03 PM
This conference is long awaited and much needed following the demise of ICAAC. I can’t wait to see how this develops @asm.org
asm.org/Press-Releas...
asm.org/Press-Releas...
Once again, it was inspiring to see the creative uses of the data from the challenge participants
amr.vivli.org/winners-anno...
amr.vivli.org/winners-anno...
Winners Announced for the 2024 AMR Surveillance Data Challenge, funded by GARDP, Paratek, Pfizer and Vivli - Vivli AMR
Vivli is pleased to announce the awardees of the 2024 AMR (Antimicrobial Resistance) Surveillance Data Challenge. The Data Challenge aims to stimulate and support the ...
amr.vivli.org
November 13, 2024 at 2:49 PM
Once again, it was inspiring to see the creative uses of the data from the challenge participants
amr.vivli.org/winners-anno...
amr.vivli.org/winners-anno...